Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $58.6 million.

  • Stoke Therapeutics' Shares Outstanding (Weighted Average) rose 403.01% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.6 million, marking a year-over-year increase of 403.01%. This contributed to the annual value of $54.0 million for FY2024, which is 2276.18% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Shares Outstanding (Weighted Average) of $58.6 million as of Q3 2025, which was up 403.01% from $58.4 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $58.6 million in Q3 2025 and a low of $37.4 million during Q1 2022
  • Moreover, its 4-year median value for Shares Outstanding (Weighted Average) was $44.3 million (2023), whereas its average is $47.8 million.
  • In the last 5 years, Stoke Therapeutics' Shares Outstanding (Weighted Average) surged by 2727.84% in 2024 and then soared by 403.01% in 2025.
  • Stoke Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $38.9 million in 2022, then grew by 13.1% to $44.0 million in 2023, then rose by 22.76% to $54.0 million in 2024, then increased by 8.52% to $58.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $58.6 million in Q3 2025, compared to $58.4 million in Q2 2025 and $57.9 million in Q1 2025.